$29.53
0.19% today
Nasdaq, Feb 28, 04:48 pm CET
ISIN
US45258D1054
Symbol
IMCR
Sector
Industry

Immunocore Holdings plc - ADR Stock price

$29.58
-2.68 8.31% 1M
-6.57 18.17% 6M
+0.08 0.27% YTD
-40.87 58.01% 1Y
+7.48 33.85% 3Y
+3.58 13.77% 5Y
+3.58 13.77% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-1.19 3.87%
ISIN
US45258D1054
Symbol
IMCR
Sector
Industry

Key metrics

Market capitalization $1.48b
Enterprise Value $1.09b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 52.31
EV/Sales (TTM) EV/Sales 3.52
P/S ratio (TTM) P/S ratio 4.77
P/B ratio (TTM) P/B ratio 4.13
Revenue growth (TTM) Revenue growth 24.19%
Revenue (TTM) Revenue $310.29m
EBIT (operating result TTM) EBIT $-70.37m
Free Cash Flow (TTM) Free Cash Flow $20.90m
Cash position $820.38m
EPS (TTM) EPS $-1.03
P/E forward negative
P/S forward 4.16
EV/Sales forward 3.07
Short interest 16.72%
Show more

Is Immunocore Holdings plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Immunocore Holdings plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Immunocore Holdings plc - ADR forecast:

12x Buy
75%
3x Hold
19%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Immunocore Holdings plc - ADR forecast:

Buy
75%
Hold
19%
Sell
6%

Financial data from Immunocore Holdings plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
310 310
24% 24%
100%
- Direct Costs 6.94 6.94
11% 11%
2%
303 303
22% 22%
98%
- Selling and Administrative Expenses 147 147
1% 1%
47%
- Research and Development Expense 222 222
42% 42%
72%
-66 -66
20% 20%
-21%
- Depreciation and Amortization 4.20 4.20
-
1%
EBIT (Operating Income) EBIT -70 -70
19% 19%
-23%
Net Profit -51 -51
8% 8%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Immunocore Holdings plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunocore Holdings plc - ADR Stock News

Neutral
Seeking Alpha
one day ago
Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries ...
Neutral
Seeking Alpha
2 days ago
Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Corporate Development Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Tyler Van Buren - TD Cowen Eric Schmidt - Ca...
Neutral
GlobeNewsWire
2 days ago
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025
More Immunocore Holdings plc - ADR News

Company Profile

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Bahija Jallal
Employees 493
Founded 2021
Website immunocore.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today